Monte Rosa Therapeutics has priced an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share, together with pre-funded warrants to purchase 1,375,000 shares of common stock at a price of $23.9999 per warrant. The warrants carry an exercise price of $0.0001 per share, reflecting a nominal premium to facilitate certain large-institution investors. All securities are being sold by Monte Rosa, and there will be no secondary sales by existing shareholders.

Before deducting underwriting discounts, commissions and offering expenses, the offering is expected to generate approximately $300 million in gross proceeds. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions, which if exercised in full would add roughly $45 million to gross proceeds.

The offering is being conducted pursuant to a shelf registration statement filed with the U.S. Securities and Exchange Commission on March 20, 2025, which was declared effective on March 31, 2025 (File No. 333-285942). A preliminary prospectus supplement has been filed with the SEC, and the offering is expected to close on or about January 12, 2026, subject to customary closing conditions. Jefferies, TD Cowen and Piper Sandler are serving as joint book-running managers, while Wedbush PacGrow and LifeSci Capital are passive bookrunners.

Proceeds from the capital raise will fortify Monte Rosa’s balance sheet as it advances three clinical-stage molecular glue degrader programs targeting oncology, autoimmune and inflammatory diseases. Management has indicated that the funds will support ongoing QuEEN™ discovery engine efforts—integrating AI-guided chemistry, structural biology and proteomics—and expand its collaborations with major pharmaceutical partners in immunology, oncology and neurology.